Met-enkephalin vs Somatostatin
Head-to-head comparison of Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and Somatostatin (Somatostatin-14) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Met-enkephalin | Somatostatin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Tyr-Gly-Gly-Phe-Met | Somatostatin-14 |
| Molecular Weight | 573.67 Da | 1637.85 |
| Half-Life | 1-5 minutes in plasma | 1-3 min |
| Amino Acids | 5 | 14 |
| Typical Dose | 0.1-5 ug per animal | N/A|N/A |
| Route | Intrathecal / intracerebroventricular | IV/SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 1200 | 84 |
| Research Status | Pre-clinical | Approved |
Met-enkephalin Benefits
- ✓endogenous opioid signaling
- ✓analgesic reference ligand
- ✓spinal antinociception
- ✓neurochemical pain-pathway probe
Somatostatin Benefits
- ✓nociceptive inhibition
- ✓anti-inflammatory signaling
- ✓visceral pain modulation
Met-enkephalin Dosing
Intrathecal 0.1-5 ug per animal|Intracerebroventricular 0.1-2 ug per animal|In vitro 1-100 nM
Somatostatin Dosing
N/A|N/A
Met-enkephalin Side Effects
- ⚠sedation at higher exposure
- ⚠constipation-like opioid effects
- ⚠rapid enzymatic degradation
Somatostatin Side Effects
- ⚠hyperglycemia
- ⚠bradycardia
- ⚠GI upset
Research Overview
Met-enkephalin
Met-enkephalin has been extensively used in receptor pharmacology and nociception studies to map mu and delta opioid biology. The main limitation in translational work is very short half-life from peptidase cleavage and poor systemic stability.
Somatostatin
Somatostatin reduces release of multiple excitatory mediators and can suppress pain signaling in preclinical and limited translational work. Its analgesic use is not standard, but the peptide is real and mechanistically relevant to pain control.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.